Cerebrolysin Therapy

Cerebrolysin's neuropeptide mixture acts through multiple neurotrophic mechanisms simultaneously. Its components have been shown to exhibit BDNF-like, NGF-like, and CNTF-like activity, promoting neuronal survival, differentiation, and synaptic plasticity. The preparation supports neurogenesis (formation of new neurons) and synaptogenesis (formation of new synaptic connections) while protecting existing neurons from oxidative stress and excitotoxicity. Cerebrolysin also modulates the amyloid cascade by influencing APP processing and reducing amyloid-beta aggregation. Its low molecular weight allows the neuropeptides to cross the blood-brain barrier, which is a significant advantage over full-length neurotrophic proteins that cannot access the CNS from peripheral administration.

Cerebrolysin is sought by patients dealing with significant cognitive decline who are looking for neuropeptide-based support with a substantial evidence base. Post-stroke and traumatic brain injury patients seeking enhanced neurological recovery are common candidates. It is also popular among individuals with a family history of neurodegenerative conditions who wish to proactively support brain health, and among high-performing professionals seeking to maintain cognitive sharpness.

Cerebrolysin is administered via intramuscular or intravenous injection. IV administration is preferred for higher doses. Standard neurological protocols typically involve daily injections for 10 to 20 consecutive days, repeated at regular intervals. Dosing ranges from 5 to 30 mL depending on the indication and severity of the neurological concern. The specific protocol is determined by the treating clinician based on the patient's neurological assessment.